Abstract. While the leukocyte integrin lymphocyte function-associated antigen (LFA)-I has been demonstrated to bind intercellular adhesion molecule (ICAM)-I, results with the related Mac-1 molecule have been controversial. We have used multiple cell binding assays, purified Mac-1 and ICAM-1, and cell lines transfected with Mac-1 and ICAM-1 cDNAs to examine the interaction of ICAM-1 with Mac-1. Stimulated human umbilical vein endothelial cells (HUVECs), which express a high surface density of ICAM-1, bind to immunoaffinity-purified Mac-1 adsorbed to artificial substrates in a manner that is inhibited by mAbs to Mac-1 and ICAM-1. Transfected murine L cells or monkey COS cells expressing human ICAM-1 bind to purified Mac-1 in a specific and dose-dependent manner; the attachment to Mac-1 is more temperature sensitive, lower in avidity, and blocked by a different series of ICAM-1 mAbs when compared to LFA-1. In a reciprocal assay, COS cells cotransfected with the o~ and/3 chain cDNAs of Mac-1 or LFA-1 attach to immunoaffinity-purified ICAM-1 substrates; this adhesion is blocked by mAbs to ICAM-1 and Mac-1 or LFA-1. Two color fluorescence cell conjugate experiments show that neutrophils stimulated with fMLP bind to HUVEC stimulated with lipopolysaccharide for 24 h in an ICAM-I-, Mac-l-, and LFA-l-dependent fashion. Because cellular and purified Mac-1 interact with cellular and purified ICAM-1, we conclude that ICAM-1 is a counter receptor for Mac-1 and that this receptor pair is responsible, in part, for the adhesion between stimulated neutrophils and stimulated endothelial cells.
function-associated antigen (LFA)-I has been demonstrated to bind intercellular adhesion molecule (ICAM)-I, results with the related Mac-1 molecule have been controversial. We have used multiple cell binding assays, purified Mac-1 and ICAM-1, and cell lines transfected with Mac-1 and ICAM-1 cDNAs to examine the interaction of ICAM-1 with Mac-1. Stimulated human umbilical vein endothelial cells (HUVECs), which express a high surface density of ICAM-1, bind to immunoaffinity-purified Mac-1 adsorbed to artificial substrates in a manner that is inhibited by mAbs to Mac-1 and ICAM-1. Transfected murine L cells or monkey COS cells expressing human ICAM-1 bind to purified Mac-1 in a specific and dose-dependent manner; the attachment to Mac-1 is more temperature sensitive, lower in avidity, and blocked by a different series of ICAM-1 mAbs when compared to LFA-1. In a reciprocal assay, COS cells cotransfected with the o~ and/3 chain cDNAs of Mac-1 or LFA-1 attach to immunoaffinity-purified ICAM-1 substrates; this adhesion is blocked by mAbs to ICAM-1 and Mac-1 or LFA-1. Two color fluorescence cell conjugate experiments show that neutrophils stimulated with fMLP bind to HUVEC stimulated with lipopolysaccharide for 24 h in an ICAM-I-, Mac-l-, and LFA-l-dependent fashion. Because cellular and purified Mac-1 interact with cellular and purified ICAM-1, we conclude that ICAM-1 is a counter receptor for Mac-1 and that this receptor pair is responsible, in part, for the adhesion between stimulated neutrophils and stimulated endothelial cells.
Primary event in the immune system's response to infectious agents is the recruitment of circulating neutrophils to the inflammatory site. Adhesion to the endothelium is the prerequisite physical step for extravasation to the peripheral site of injury. Neutrophil localization has been examined on a molecular level to define both the sequence of events that promotes neutrophil exit from the bloodstream and the cognate proteins on the surface of neutrophils and the endothelial cells that coordinate this interaction.
The CDll/CDI8 family defines three high molecular weight, cell surface heterodimeric glycoproteins that have a broad distribution on leukocytes (53) . This family, known as the leukocyte integrins, consists of lymphocyte functionassociated antigen (LFA)1-1 (CDlla/CD18; ot 175,000 Mr), Macq (CDllb/CD18; ct 160,000 Mr), and p150,95 (CDllc/ CD18; ot 150,000 Mr); the three proteins share a common 13 (CD18) chain (95,000 Mr) that is noncovalently associated with each unique a chain. These proteins are critical for adhesive functions in the immune system (29) : mAbs to LFA-I block leukocyte adhesion to endothelial cells (16, 56) nally defined as counter-receptors for LFA-1 (41, 54, 58, 59) . ICAM-1 is a 90,000-110,000 M, glycoprotein with a low RNA message level and moderate surface expression on unstimulated endothelial cells; lipopolysaccharide (LPS), interleukin (IL)-I, and rumor necrosis factor ot strongly upregulate ICAM-1 mRNA and surface expression with peak expression at ~18-24 h (16, 58) . LFA-I-ICAM-1 interaction is responsible partially for lymphocyte (16, 42) , monocyte (5, 43, 61) , and neutrophil (34, 56) adhesion to endothelial cells. ICAM-2 is a 55,000 M, glycoprotein with high mRNA level (59) and surface expression (A. de Fougerolles and T. Springer, manuscript in preparation) in both unstimulated and stimulated endothelial cells. Unstimulated endothelial cells bind purified LFA-1 in a manner that is inhibited by a combination of ICAM-1 and ICAM-2 mAbs (A. de Fougerolles and T. Springer, manuscript in preparation).
Recent studies (55, 56) by one group suggest that LFA-1 and Mac-1 cooperate in neutrophil adherence to endothelial cells; unstimulated neutrophils bind primarily through surface LFA-1 while formyl methionine-leucine-phenylalanine (fMLP) activated neutrophils attach mostly through Mac-1. Mac-1 and LFA-1 both may be interacting with ICAM-1 since a mAb to ICAM-1 thoroughly blocks CD18-dependent, fMLP-stimulated neutrophil adhesion to unstimulated endothelial cells (55) . Because mAbs to LFA-1 and Mac-1 also abrogate neutrophil attachment to planar membranes containing ICAM-1 (56), this group concludes that neutrophil adhesion to endothelial cells is partially ICAM-1-LFA-1-and ICAM-1-Mac-I-dependent. In contrast, a second group reports (34) that when phorbol ester-stimulated neutrophils adhere to unstimulated endothelial cells, while both Mac-1 and LFA-1 are involved, only LFA-1 interacts with ICAM-1. In addition, they find that when macrophages are plated on ICAM-1 substrates, only LFA-1 is down-modulated from the apical portion of the cell surface. This group concludes that Mac-1 does not bind ICAM-1, but rather, it interacts with an uncharacterized endothelial cell surface receptor.
To resolve this paradox, we use immunoaflinity-purified Mac-1 and ICAM-1, and transfected cells expressing ICAM-1, Mac-l, and LFA-1, to show in reciprocal adhesion studies that ICAM-1 is a counter receptor, not only for LFA-1, but also for Mac-1. Cell-cell binding studies demonstrate that neutrophil Mac-1 interacts with ICAM-1 expressed on human umbilical vein endothelial cells (HUVECs). These findings also suggest that Mac-1 interacts with at least one additional cellular ligand, besides ICAM-1, on the surface of endothelial cells.
Materials and Methods

mAbs
The following murine mAbs against human antigens were from ascites: LPM19c (anti~CDllb, IgG2a, gift of Dr. K. Poldman, Oxford) (63), W6/32 (anti-HLA A, B, C, IgG2a) (7), TS1/22 (anti-CDlla, lgGl) (52), YFC51.1 (anti-CDl8, rat IgG2b, gift of Dr. H. Waldmann, Cambridge) (63), CBRIC2/I and CBRIC2/2 (anti-ICAM-2, IgG2a; A. de Fongerolles and T. Springer, manuscript in preparation), and TS2/16 (anti-CD29, IgG1) (52) . The following ICAM-1 mAbs were used as purified IgG: CL203 (37) (gift of Dr. S. Fermne), LB-2 (12) (giR of Dr. E. Clark), and 84H10 (38) . RRU1 FOlY2 (IgG1) (50) were prepared by pepsin digestion after Protein A affinity chromatography (48) . R6.5 (IgG2a) (55) IgG and Fab were a generous gift of Dr. R. Rotlflein, Boehringer lngelheim (Ridgefleld, CT). CBRIC1/I, CBRIC1/2, CBRIC1/3, CBRIC1/4 (anti-ICAM-1 mAb, S. Stacker and T.
Springer, manuscript in preparation), M1/42 (anti-H-2, rat IgG2a) (57) , and X63 (nonbinding antibody, IgGl) were used as tissue culture supernatants. For inhibition assays ascites were used at 1:400 dilutions, purified IgG were used at 20-25 #g/ml, FalY2 were used at 20 #g/ml, Fab were used at 50 #g/mi, and tissue culture supernatants were used at 1:2. In inhibition experiments, the difference between our binding mAb and media controls was <30%. Protein A-purified TS1/18 (anti-CDlS, IgG1) (52) and LM2/1 (antiCDllb, IgG1) (44) were iodinated and used for site density measurements as described (17) ; TSI/18 recognizes only the intact a/13 beterodimer.
Protein Purification
Mac-1 is purified from leukocyte lysates by a modification of a previous procedure (17, 46) . Briefly, to obtain 500/~g of the purified functional heterodimer, 10 g of frozen peripheral blood leukocytes are solubilized in 200 ml of lysis buffer (100 mM Tris-HC1, pH 8.0, 150 mM NaC1, 2 mM MgClz, 1% Triton X-100, 5 mM iodoacetamide, 0.025% NAN3, 1 mM PMSF, 1 mM diisopropylfluorophosphate, 0.2 TIU/mi Aprotinin) for 1 h at 4°C while stirring gently. The resultant lysate is centrifuged at 10,000 g for 2 h at 4°C; the supernatant is decanted and then ultracentrifuged at 100,000 g (Ti45; Beckman Instruments, Inc., Palo Alto, CA) for 1 h. The clarified lysate is precleared with human IgG coupled to Sepharose CL-4B; 40 #1 of a 1:1 slurry of lgG-Sepharose is added per mi of lysate and rotated overnight at 4°C. The Sepharose is pelleted and the precleared lysate is then passed over an LM2/1 (anti-CD1 lb; IgG1) immunoaflinity column (bed volume 6 mi, 3 mg/mi of LM2/I) that is prepared by attaching protein A-purified LM2/1 to cyanogen bromide-activated Sepharose (40) . The column is preequilibrated with 10 bed volumes of 50 mM Tris-HCl, pH 8.0, 150 mM NaCI, 2 mM MgC12, 0.1% Triton X-100, the precleared lysate is loaded at 10 mi/h. The column is sequentially washed at 20 mi/h with 10 bed volumes of 50 mM Tris-HC1, pH 8.0, 150 mM NaC1, 2 mM MgCI2, 0.1% Triton X-100, and then 10 bed volumes of 50 mM Tris-HC1, pH 8.0, 150 mM NaC1, 2 mM MgC12, 1% n-octyl ~-v-glucopyranoside. Mac-I is eluted with 5 bed volumes of 50 mM triethylamine (TEA), pH 10.0, 300 mM NaCI, 2 mM MgCI2, I% n-octyl ~-D-glucopyranoside into tubes with neutralizing buffer (10% by volume I M Tcis-HCl, pH 7.4). The peak fractions are pooled, aliquoted, and stored at -80°C for 3-6 mp without loss of activity.
LFA-I is purified by immunoaffinity chromatography as described previously (17) except peripheral blood leukocyte lysates were substituted. ICAM-1 is purified by immunoaffinity chromatography as described previously (41) .
SDS-PAGE
Protein samples are run on reducing (5% ~-mercaptoethanol) SDS 7-10% polyacrylamide gels (31) and silver stained (47) .
Tissue Culture, Transfection, and Cell Preparation
COS cells are grown on 10-or 15-cm tissue culture-treated plates (Falcon Labware, Oxnard, CA) in RPMI 1640 with 10% FCS, 5 w_M glutamine, and 50 #g/ml gentamycin. Cells are transfected at '~50-60% confluency in 10-cm plates with 4-6 #g of CsCi-purified (39) ICAM-1 eDNA (60) or cotransfected with 6 #g Mac-1 a or LFA c~ plus 6 #g ~ eDNA (21, 32) by the DEAE-Dextran method for 4 h at 37°C (6, 26) . After 72 h cells are eluted from the tissue culture plates before functional assays with PBS, 5 mM EDTA at 37°C for 5 min.
ICAM-1 + L cell stables are generated as described (ll). Briefly, murine L cells (thymidine kinase [tK]-) are seeded onto 6-cm tissue culture dishes and grown to 10-20% confluency over 2 d. ICAM-1 cDNA in the plasrnid CDM8 (60) (10 #g) and plasmid containing a thymidine kinase selection marker (100 ng) are mixed with 0.2 mi CaCI2 and 0.2 mi of 50 mM N-,N-bis-2-amino-ethanesulfonic acid, 280 mM NaC1, 1.5 mM Na2HPO4, pH 6.95, and incubated at room temperature for 10-20 min. The calcium phosphate-DNA solution (0.4 mi) is added dropwise to the plated cells and incubated at 35°C in a 3% CO2 incubator. 24 h later, the cells are washed with regular DME media and grown at 37°C in a 5% CO2 incubator until day 3 when HAT (100/~M hypoxanthine, 400 nM aminopterin, 16 #M thyrnidine) selection is initiated. Cells with high ICAM-1 expression are identified by flow cytometry after single colony picks with a cloning cylinder. ICAM-1 + L cells are maintained in a selection media that consists of DME with 10% heat inactivated FCS, 5 mM glutamine, 50 ttg/ml gentamycin, and supplemented with HAT. Untransfected L cells are maintained in DME without HAT.
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HLrVECs are cultured to low passage number (2-5) on tissue culture plates precoated with fibronectin (50 ~g/ml) in M199 media supplemented with 20% heat-inactivated FCS, 100/~g/ml heparin, 100/~g/ml endothelial cell growth factor, 10 mM HEPES, pH 7.3, 5 mM glutamine, and 50 ttg/ml gentamyein (16) . LPS treatment is performed by adding 1 ~g/ml of E. coli lipopolysaccharide (endotoxin) 24 h before harvesting of cells. Cytokine stimulation is performed by addition of 5 U/ml of rlL-115 (Genzyme, Cambridge, MA). To elute HUVEC for the two color fluorescence studies, cells are treated with PBS, 5 mM EIYI'A at 370C for 5-10 rain.
Neutrophils are isolated from the whole blood of healthy volunteers by dextran sedimentation, Ficoll gradient centrifugation, and hypotonic lysis (19) . Before experimental manipulation, neutrophils are stored at room temperature in HBSS, 10 mM HEPES, pH 7.3, 0.5 % human serum albumin (HBSS/HSA).
Cell Conjugation Experiments
The dual fluorescence cell conjugate assay is performed by a modification of a published protocol (35) . Briefly, l0 s neutrophils are washed twice in HBSS/HSA, resuspended in I0 ml of a filtered (0. 
Cell Binding to Purified Proteins
Purified Mac-I, LFA-1, and ICAM-1 are diluted from 1/8-1/120 depending on protein content (judged by SDS-PAGE and RIA; 17) in 20 mM Tris-HCl, pH 7.4, 150 mM NaC1, 2 mM MgCI2 with an octyl glucoside detergent concentration ranging from 0.1% to 0.01% and plated over the entire surface of 35-ram Petri dishes, as a 40-~1 demarcated spot on 60-ram Petri dishes, or in 50/~1 for each well of 96-well plates (Linbro-Titertek Flow Labs, McLean, VA) for 90 rain at room temperature (59) . Plates and dishes are blocked subsequently by three washes with and subsequent incubation in PBS, 2 mM M8C12, 0.5% HSA (PBSMI-I) for 2 h at 37"C. For the COS cell adhesion assay to Mac-l, lower site densities of Mac-1 (<500 sites/~m 2) were used to avoid a background cell binding that is due to the expression of an endogenous ligand for Mac-1 on the COS cell surface (M. Diamond and 1". Springer, unpublished observations); this site density allowed ICAM-1 expressing COS cells to adhere but did not sustain binding of vector alone transfected COS cells.
For the 96-well plate assay, unstimulated, 18-h IL-lfl or 24-h LPSstimulated HUVECs are eluted from tissue culture plates with PBS, 5 mM EDTA, washed twice in HBSS/HSA, resuspended to 106 eells/ml, labeled with 50 itCilml 51Cr for 1 h at 37*C, washed twice in HBSS/HSA, twice in PBSMH and 0.2% glucose, and along with the Mac-l-treated plates are preincubated for 25 rain at room temperature with appropriate antibodies. HUVECs (50/~1 of 106 cells/ml) are added to each well and the binding assay is performed at room temperature for 1 h. Unbound cells are removed by a high stringency aspiration wash procedure that uses a 26 gauge needle (17) . Bound cells are eluted with 0.2 M NaOH or PBS, 25 mM EDTA, and quantitated by 3' emission. The same protocol is used with L cells except that RPMI, 20 mM HEPES, pH 7.3, 5% FCS, 0.1% HSA is substituted as the binding buffer, the cells are centrifuged at 300 rpm for 5 rain onto Mac-I substrates, the incubation is performed at 37°C, and only two aspiration washes are required.
For the 35-and 60-ram Petri dish assays, transfected COS cells or L cells are eluted from tissue culture plates with PBS, 5 mM EI3q'A or RPMI,, 10 mM EDTA. COS cells are washed twice in HBSS/HSA, resuspended in HBSS/HSA to 8 × 105 cells/ml, and labeled with 50 t~Ci/ml 5tCr for 1 h. Excess label is washed out and the COS cells are resuspended to 8 × 105/ml in PBS, 1.5 mM MgCI2, 0. 
Results
Adhesion of Mac-1 and LFA-1 Transfectants to Purified ICAM-1
Previous studies (56) which suggest that Mac-1 on neutrophils binds to ICAM-1 are complicated by the presence of multiple adhesion receptors on neutrophils, e.g., neutrophils express significant quantities of both LFA-1 and Mac-1. We utilized a purified protein-transfectant cell binding assay where each of the ligand pairs could be examined independently for adhesion (32) . COS cells cotransfected with the cDNAs for the common 13 subunit and either the Mac-1 or LFA-1 ot subunit were assayed for binding to purified ICAM-1 coated on a plastic substrate. Surface expression averaged 30% for Mac-1 and 40% for LFA-1 as determined by immunoflUOrescence flow cytometry (Fig. 1 B) . Transfected COS cells expressing Mac-1 and LFA-1 bind purified ICAM-1 ( Fig.  1 A) , while cells transfected with the/3 chain alone do not bind (data not shown; 32). Adhesion is specific as mAbs to LFA-1, Mac-I, and ICAM-1 inhibit attachment, whereas a control mAb that binds the monkey homologue of CD29 does not inhibit. The adhesion of Mac-1 transfectants is weaker occurs at 37°C but not at 230C, whereas COS cells transfected with LFA-1 bind to ICAM-1 at 230C (data not shown).
Immunoaffinity Purification of Functional Mac-I
To gain additional evidence for an interaction between Mac-1 and ICAM-1, we wanted to test the reciprocal assay, whether ceils bearing ICAM-1 bound to purified Macq. To purify Mac-l, we modified a procedure used to obtain LFA-1 in a form that was functional and in which the o~ and/~ chains remained noncovalently associated (17) . Peripheral blood leukocytes were lysed in Triton X-100 in the presence of Mg 2+, and the Mac-1 otB complex was bound to an LM2/1 mAb affinity column. Triton X-lO0 was exchanged with the dialyzable detergent n-octyl-B-D-glucopyranoside. Elution conditions of varied salt, divalent cation concentration, and pH were tested and optimized for yield and the ability to reprecipitate the heterodimer. The optimum buffer contained 50 mM triethylamine, pH 10.0, 300 mM NaC1, and 2 mM Mg 2+. Mac-1 obtained by this procedure was substantially pure, and migrated on reducing SDS-PAGE as two bands with Mr of 160,000 and 95,000 (Fig. 2) , consistent with our previous observations (46). Immunoprecipitation with the Figure 2 . SDS-PAGE of purified Mac-l.
Purified Mac-1 (10 #1 of a 2-ml fraction from an LM2/1 mAb affinity column) is subjected to reduction, SDS 7.5 % PAGE, and silver staining. Molecular weight standards are marked to the left. anti-fl mAb TS1/18 of the purified material yielded the beterodimer, indicating that the two chains, after elution, remain associated (data not shown). This material has complement receptor type three (CR3) activity as it binds specifiearly to iC3b-coated erythrocytes but not erythrocytes coated only with anti-Forsmann antibody (15) . Approximately 500 ~g of intact Mac-1 was recovered from 10 g of leukocytes.
Adhesion of Cells Transfected with ICAM-1 cDNA to Purified Mac-1 and LFA-1
To test whether cells bearing ICAM-1 interact with Mac-l, COS cells were transfected with the ICAM4 eDNA and allowed to settle on Mac-l-coated substrates. Surface expression of ICAM-1 on transfected COS cells averaged 50-60 % (Fig. 3 B) , while vector-transfected COS cells showed no expression (Fig. 3 A) . COS cells expressing ICAM-1 adhere to purified Mac-1 (Fig. 4 A) , whereas cells transfected with vector alone do not adhere (Fig. 4/9 ). The binding is specific as it is blocked completely with mAbs to Mac-1 o~ (LPM19c) or ICAM-1 (a mixture of R6.5 and RR1/1) (Fig. 4, B and C) .
To assess more quantitatively the strength of the interaction between Mac-1 and ICAM-1, we performed a dose response analysis. Because of the variation between experiments in the percent of COS cells expressing ICAM-1 and the heterogeneity in the level of ICAM-1 expression between cells (Fig. 3 B) , stable transfectants expressing human ICAM-1 in murine L cells were generated as described in Materials and Methods (11) . Colonies were selected in which 100% of the L cells expressed high amounts of human ICAM-1 (Fig. 3 D) .
Titration experiments were performed in which ICAM-1 + L cells were allowed to hind to substrates coated with a wide range of Mac-1 site densities (Fig. 5) . L ceils expressing ICAM-1 adhered to Mac-1 in a dose-dependent fashion with a threshold of "~ 250 sites//~n 2 before significant adhesion is seen. The adhesion is specific as plates pretreated with mAb to Mac-1 ot (LPM19c), cells pretreated with mAhs to ICAM-1 (a mixture of RR1/1 and R6.5), and untransfected L cells did not attach.
Parallel experiments were performed on LFA-1-and Mac-1-coated substrates to determine the difference in relative avidity for ICAM-1 using a lower stringency wash protocol (Fig. 6) . The amount of Mac-1 and LFA-1 bound to substrate was determined by RIA with a mAb to the common subunit. ICAM-1 + L cells adhered tO LFA-1 substrates with a slightly higher avidity as the binding isotherm for purified Mac-1 is shifted to a higher site density. The difference in avidity is consistent with the observation that when COS cells express ICAM-1 at low levels, they adhere to LFA-1 but not Mac-1 substrates (data not shown). Binding of ICAM-1 ÷ L cellS tO Mac-1 is more temperature sensitive than binding to LFA-1 (Fig. 7) . Despite equivalent site densities of LFA-1 and Mac-1 on the substrate, cells adhere strongly to LFA-1 but weakly to Mac-1 at room temperature, while there is little or no difference in the quantitative adhesion at 37°C.
Adhesion of HUVEC to Purified Mac-I
To confirm that stimulated HUVECs adhere to Mac-1 in an ICAM-1--dependent fashion, we tested their ability to bind Mac-1 substrates. HUVECs, when stimulated for 18-24 h with IL-1/~ or LPS, bind purified Mac-1 under high stringency wash conditions (Fig. 8) . Adhesion is specific and primarily ICAM-1 dependent since it is inhibited by mAbs to ICAM-1 (82% for LPS, 66% for IL-1B) and Mac-1 ot (>95% in both cases) but not by control mAb. Unstimnlated HUVECs, which express lower amounts of ICAM-1 (18), do not attach significantly to purified Mac-1 at this stringency of wash. However, if the assay is performed under gentler wash conditions, unstimulated HUVECs adhere to purified Mac-1 in a dose-dependent manner (Fig. 9 ). There is complete inhibition with mAb to Mac-1 but only a small inhibition of unstimulated HUVEC adhesion with mAb to ICAM-1, suggesting the presence of an additional ligand(s) for Mac-1 on HUVEC. mAbs to ICAM-2 that block its interaction with LFA-1, alone or in combination with ICAM-1 mAbs, have little effect on HUVEC adhesion to Mac-1 (Fig. 9 and data not shown).
Difference among ICAM-I mAbs in Blocking Adhesion to Mac-1 and LFA-1
Our reciprocal adhesion assays show that both Mac-1 and LFA-1 bind to ICAM-1. This result prompts the question of which epitopes on ICAM-1 are involved in interactions with LFA-1 and Mac-1. Studies above were performed with a mixture of RRU1 and R6.5 mAb. We examined ICAM-I* L cell adhesion to both Mac-1 andLFA-1 in the presence of a panel of individual ICAM-1 mAb. In addition to previously characterized ICAM-1 mAbs (RR1/1, R6.5, LB-2, CL203, 84H10), four new ICAM-1 mAbs were generated against HUVEC stimulated with IL-1/3 (S. Stacker and T. Springer, manuscript in preparation). There is a striking difference among mAbs to ICAM-1 in their ability to block adhesion of ICAM-1 + L cells to Mac-1 and LFA-1 (Fig. 10) . As previously reported (34, 38, 41, 50, 55) 
Neutrophil-HUVEC Conjugate Formation
While the reciprocal assays of cell binding to purified protein strongly suggest that Mac-1 interacts with ICAM-1, we wanted to confirm that this interaction is physiologic, i.e., that it could occur between cells that both normally express Mac-1 and ICAM-1 and adhere to each other in vivo. We used fMLP-actiwted neutrophils which strongly express Mac-1 (45) and 24-h LPS-treated HUVECs which express high levels of ICAM-1 (16) but low amounts of.ELAM-1 (10, 49) . To characterize adhesion quantitatively, a two color fluorescence conjugate assay was developed in which neutrophils ~d HUVECs are labeled with red and green fluorescent compounds, respectively. This system differs from the binding of neutrophils to HUVEC monolayers under static conditions and removal of nonadherent cells by 1 g sedimentation, an assay that was used in a previous report (56) that described ICAM-1 as a ligand for Mac-1. In our system, neutrophil-endothelial cell heterotyplc conjugates form in suspension while the cells are gently agitated.
Chemotactic stimulation of neutrophils resulted in a significant increase in conjugation with HUVEC over the baseline conjugate formation of unstimulated neutrophils (Table I ). There was a three-to fourfold increase in the number of HUVECs conjugated with neutrophils after stimulation. When TS1/22, an anti-LFA-1 ot mAb was added, there was a slight but not statistically significant inhibition of conjugate formation. If an mAb to the Mac-1 ot subunit was added, there was a significant inhibition (73 %) of stimulated cell conjugates. A combination of anti-LFA-1 and anti-Mac-1 mAbs or an antibody against the common fl chain showed the greatest inhibition (88-98%). A mixture of R6.5 Fab and RR1/1 Fab'2 fragments decreased conjugate formation by 48 %. Since this inhibition is greater than that of LFA-1 antibodies alone, the results suggest that both LFA-1 and Mac-1 inferact with ICAM-1. Because the CD18-dependent adhesion cannot be inhibited solely with mAbs to ICAM-1, LFA-1 and/or Mac-1 may be interacting with additional ligands. For LFA-1, ICAM-2 is a strong possibility, yet it does not appear that Mac-1 binds to ICAM-2 ( Fig. 9 ) and, thus, other endothelial cell surface counter receptors may be involved.
Discussion
We prove that Mac-l, like LFA-1 (41), is a counter-receptor for ICAM-1 by demonstrating that purified Mac-1 mediates cell adhesion dependent on ICAM-1, and reciprocally that purified ICAM-1 mediates cell adhesion dependent on Mac-1. Cells transfected with specific cDNAs of putative counter receptors were used to eliminate complications associated with additional receptor-ligand interactions. We show that ICAMq + transfectants and Mac-1 + transfectants bind purified Mac-1 and ICAM-1, respectively. To rule out the possibility that this result is an effect of the experimental system, we show a Mac-l, ICAM-l-dependent adhesion between stimulated endothelial ceils and purified Mac-1. We also demonstrate a Mac-I-ICAM-1 interaction in a cell-cell context as stimulated Mac-1 + peripheral blood neutrophils form cell conjugates with ICAM-1 + HUVEC in a manner that is inhibited with Mac-1 and ICAM-1 mAbs.
The binding of ICAM-1 to both Mac-1 and LFA-1 shows that an immunoglobulin-like molecule can adhere to more [13] and the surface area of resting neutrophils [22] . The site density of LFA-1 on a lymphocyte is calculated from the number of molecules of LFA-1 on a lymphocyte [64] and a mathematical approximation for the surface area of a lymphocyte [255/F: diameter = 9 it].) Although we used a mAb to the common/3 subunit to quantitate Mac-1 and LFA-1 site densities, and the mAb reacts with associated but not free/3 subunlt (27), we cannot ascertain what percentage of protein on pl~tic is in an active conformation that can bind to ICAM-1. Definitive measurement of the absolute affinity of Mac-1 and LFA-1 for ICAM-1 remains to be done. Another feature distinguishing the interaction with LFA-1 and Mac-1 is the striking effect of temperature on adhesion.
While ICAM-1 + L and COS cells bind strongly to purified solid phase LFA-1 at room temperature (Fig. 7 , and our unpublished observations), there is a strict 37°C temperature requirement for significant adhesion to purified Mac-1 (Fig.  7) . Interaction of ICAM-l-bearing cells with purified Mac-1 also appears more energy dependent than interaction with LFA-1 (59; data not shown). The temperature and energy dependence of Mac-I-ICAM-1 interaction may be due to a requirement for greater ICAM-1 clustering on the cell surface or to a need for closer cell-substrate apposition. Consistent with the stronger interaction with LFA-1, we observed that transfected cells expressing ICAM-1 spread and flatten out more on LFA-l-coated substrates than on Mac-1 substrates (M. Diamond, O. Carpen, and T. Springer, unpublished observations).
The binding of Mac-1 to ICAM-1 demonstrates directly that Mac-1 interacts with an endothelial cell surface counter receptor. Our results agree with previous studies that show neutrophil adhesion to endothelial cells is inhibited by mAb to Mac-1 (3, 20, 65) , and that Mac-I-and LFA-l-dependent adhesion of fMLP-stimulated neutrophils to unstimulated endothelial cells (55) or ICAM-1 containing planar membranes (56) is blocked completely by a mAb to ICAM-1 (R6.5). In contrast, ICAM-1 has been reported not to be a ligand for Mac-1 (34) . In that study, neutrophils stimulated with phorbol esters adhere to unstimulated endothelial cells in a manner that is LFA-I-, Mac-l-and ICAM-l-dependent, results that agree with our findings. However, this group concluded that only LFA-1 interacts with ICAM-1 because the inhibition with LFA-1 and ICAM-1 mAbs (LB-2, 84H10) is not additive whereas the inhibition with Mac-1 and ICAM-1 mAbs is additive. The differences in the previous reports may be explained partially by the disparity in mAb selection; here we show that R6.5 mAb blocks both Mac-l-and LFA-1-ICAM-1 interactions, whereas LB2 and 84H10 mAb only inhibit LFA-I-ICAM-1 binding (Fig. 10) . Our results do not explain, however, a previous observation that when macrophages are plated on an ICAM-1 substrate, LFA-1 but not Mac-1 is down-modulated from the apical surface (34) . Our mAb blocking data is consistent with mutagenesis studies that map mAb epitopes to distinct regions of the ICAM-1 molecule (60) . RRI/1 and LB-2 map to the first NH2-terminal immunoglobulin domain whereas R6.5 maps to the second domain. Our data is also consistent with in vivo experiments (8) that show a reduction in the granulocyte infiltration into rabbit lungs inflamed with phorbol esters after pretreatment with mAbs to CD18 (R3.3) or ICAM-1 (R6.5), but not with mAb to LFA-1 (R3.1). These findings suggest that stimulated neutrophils may utilize a Mac-1-ICAM-l-dependent pathway of adhesion to mediate attachraent in vivo to inflamed endothelium.
Experiments presented here are consistent with the possibility of counter-receptors for Mac-1 distinct from ICAM-1 on the surface of unstimulated (34) and stimulated endothelial cells. In our assays, endothelial cell ICAM-1 cannot by itself account for all of the Mac-1-dependent adhesion of neutrophils. Adhesion of stimulated HUVEC to purified Mac-1 under high stringency wash conditions is only pardally (68-82%) blocked by mAb to ICAM-1 (Fig. 8) . Furthermore, there is little adhesion of unstimulated HUVEC to Mac-1 at this stringency, but when washed at a lower stringency (Fig. 9) , there is significant non-ICAM-l-dependent adhesion to purified Mac-1. This result conflicts with a report that showed that fMLP-stimulated neutrophil adhesion to unstimulated endothelial cells was blocked 84 % by a mAb to ICAM-1 (55). We do not understand the discrepancy, but it may be explained by differences in tissue culture conditions of untreated HUVEC which may induce a second ligand for Mac-1. At present, we do not understand fully the role of ICAM-2 in neutrophil adhesion to unstimulated or stimulated endothelial cells, although ICAM-I÷ICAM-2 + endothelial cells adhere to LFA-l-bearing cells or coated substrates in a manner that is Mocked by mAbs to ICAM-1 and ICAM-2 (A. de Fougerolles and T. Springer, manuscript in preparation). At present, we have no evidence for interaction of Mac-1 with ICAM-2, since mAbs to ICAM-2 do not block HUVEC adhesion to Mac-1 and ICAM-2 + COS cells do not bind to purified Mac-1 (data not shown). Thus, we hypothesize and are currently looking for a non-ICAM-1, non-ICAM-2 counter receptor for Mac-1 on the surface of unstimulated endothelial cells.
Unexpectedly, our mAb blocking data suggest that Mac-1 and LFA-1 may not share the same binding site on ICAM-1. Amino acid substitution and domain deletion mutagenesis of ICAM-1 have shown that the binding site for LFA-1 is localized in the most NH2-terminal of the five Ig-like domains of ICAM-1 (60) . Similar experiments must now be done to map the region of ICAM-1 that contacts Mac-1.
